Megan C Roberts1, Morris Weinberger2, Stacie B Dusetzina2, Michaela A Dinan2, Katherine E Reeder-Hayes2, Lisa A Carey2, Melissa A Troester2, Stephanie B Wheeler2. 1. Megan C. Roberts, Morris Weinberger, Stacie B. Dusetzina, Katherine E. Reeder-Hayes, Lisa A. Carey, Melissa A. Troester, and Stephanie B. Wheeler, University of North Carolina at Chapel Hill, Chapel Hill; Morris Weinberger, Durham Veterans Affairs Medical Center for Health Services Research; and Michaela A. Dinan, Duke Clinical Research Institute and Duke Cancer Institute, Durham, NC. mclarker@unc.edu. 2. Megan C. Roberts, Morris Weinberger, Stacie B. Dusetzina, Katherine E. Reeder-Hayes, Lisa A. Carey, Melissa A. Troester, and Stephanie B. Wheeler, University of North Carolina at Chapel Hill, Chapel Hill; Morris Weinberger, Durham Veterans Affairs Medical Center for Health Services Research; and Michaela A. Dinan, Duke Clinical Research Institute and Duke Cancer Institute, Durham, NC.
Abstract
PURPOSE: Oncotype DX (ODX) is a tumor gene-profiling test that aids in adjuvant chemotherapy decision-making. ODX has the potential to improve quality of care; however, if not equally accessible across racial groups, disparities in cancer care quality may persist or worsen. We examined racial disparities in ODX testing uptake. METHODS: We used data from the Carolina Breast Cancer Study, phase III, a longitudinal, population-based study of 2,998 North Carolina women who received a diagnosis of breast cancer between 2008 and 2014. Our primary analysis used modified Poisson regression to determine the association between race and whether ODX testing was ordered among two strata: node-negative and node-positive breast cancer. RESULTS: A total of 1,468 women with estrogen receptor-positive, human epidermal growth factor receptor-2-negative, stage I or II breast cancer met inclusion criteria. Black patients had higher-grade and larger tumors, more comorbidities, younger age at diagnosis, and lower socioeconomic status than non-black women. Overall, 42% of women had ODX test results in their pathology reports. Compared with those who did not receive ODX testing, women who received ODX testing tended to be younger and have medium tumor size and grade. Our regression analyses indicated no racial disparities in ODX uptake among node-negative patients. However, racial differences were detected among node-positive patients, with black patients being 46% less likely to receive ODX testing than non-black women (adjusted relative risk, 0.54; 95% CI, 0.35 to 0.84; P = .006). CONCLUSION: We did not find racial disparities in ODX testing for node-negative patients for whom ODX testing is guideline recommended and widely covered by insurers. However, our findings suggest that a newer, non-guideline-concordant application of ODX testing for node-positive breast cancer was accessed less by black women than by non-black women, reflecting more guideline concordant care among black women.
PURPOSE: Oncotype DX (ODX) is a tumor gene-profiling test that aids in adjuvant chemotherapy decision-making. ODX has the potential to improve quality of care; however, if not equally accessible across racial groups, disparities in cancer care quality may persist or worsen. We examined racial disparities in ODX testing uptake. METHODS: We used data from the Carolina Breast Cancer Study, phase III, a longitudinal, population-based study of 2,998 North Carolina women who received a diagnosis of breast cancer between 2008 and 2014. Our primary analysis used modified Poisson regression to determine the association between race and whether ODX testing was ordered among two strata: node-negative and node-positive breast cancer. RESULTS: A total of 1,468 women with estrogen receptor-positive, human epidermal growth factor receptor-2-negative, stage I or II breast cancer met inclusion criteria. Black patients had higher-grade and larger tumors, more comorbidities, younger age at diagnosis, and lower socioeconomic status than non-black women. Overall, 42% of women had ODX test results in their pathology reports. Compared with those who did not receive ODX testing, women who received ODX testing tended to be younger and have medium tumor size and grade. Our regression analyses indicated no racial disparities in ODX uptake among node-negative patients. However, racial differences were detected among node-positive patients, with black patients being 46% less likely to receive ODX testing than non-black women (adjusted relative risk, 0.54; 95% CI, 0.35 to 0.84; P = .006). CONCLUSION: We did not find racial disparities in ODX testing for node-negative patients for whom ODX testing is guideline recommended and widely covered by insurers. However, our findings suggest that a newer, non-guideline-concordant application of ODX testing for node-positive breast cancer was accessed less by black women than by non-black women, reflecting more guideline concordant care among black women.
Authors: Juhi Asad; Allyson F Jacobson; Alison Estabrook; Sharon Rosenbaum Smith; Susan K Boolbol; Sheldon M Feldman; Michael P Osborne; Kwadwo Boachie-Adjei; Wendy Twardzik; Paul I Tartter Journal: Am J Surg Date: 2008-10 Impact factor: 2.565
Authors: Michaela A Dinan; Xiaojuan Mi; Shelby D Reed; Bradford R Hirsch; Gary H Lyman; Lesley H Curtis Journal: JAMA Oncol Date: 2015-05 Impact factor: 31.777
Authors: Megan C Roberts; Morris Weinberger; Stacie B Dusetzina; Michaela A Dinan; Katherine E Reeder-Hayes; Melissa A Troester; Lisa A Carey; Stephanie B Wheeler Journal: Breast Cancer Res Treat Date: 2015-07-28 Impact factor: 4.872
Authors: Scott D Ramsey; William E Barlow; Ana M Gonzalez-Angulo; Sean Tunis; Laurence Baker; John Crowley; Patricia Deverka; David Veenstra; Gabriel N Hortobagyi Journal: Contemp Clin Trials Date: 2012-09-18 Impact factor: 2.226
Authors: Michael J Hassett; Samuel M Silver; Melissa E Hughes; Douglas W Blayney; Stephen B Edge; James G Herman; Clifford A Hudis; P Kelly Marcom; Jane E Pettinga; David Share; Richard Theriault; Yu-Ning Wong; Jonathan L Vandergrift; Joyce C Niland; Jane C Weeks Journal: J Clin Oncol Date: 2012-05-14 Impact factor: 44.544
Authors: Mitch Dowsett; Jack Cuzick; Christopher Wale; John Forbes; Elizabeth A Mallon; Janine Salter; Emma Quinn; Anita Dunbier; Michael Baum; Aman Buzdar; Anthony Howell; Roberto Bugarini; Frederick L Baehner; Steven Shak Journal: J Clin Oncol Date: 2010-03-08 Impact factor: 44.544
Authors: Carlos H Barcenas; Akshara Raghavendra; Arup K Sinha; Masood Pasha Syed; Limin Hsu; Modesto G Patangan; Mariana Chavez-MacGregor; Yu Shen; Gabriel H Hortobagyi; Vicente Valero; Sharon H Giordano; Naoto T Ueno; Debu Tripathy Journal: Cancer Date: 2017-02-15 Impact factor: 6.860
Authors: Katherine E Reeder-Hayes; Sophie E Mayer; Andrew F Olshan; Stephanie B Wheeler; Lisa A Carey; Chiu-Kit Tse; Mary Elizabeth Bell; Melissa A Troester Journal: Cancer Date: 2019-08-09 Impact factor: 6.860
Authors: Melissa A Troester; Xuezheng Sun; Emma H Allott; Joseph Geradts; Stephanie M Cohen; Chiu-Kit Tse; Erin L Kirk; Leigh B Thorne; Michelle Mathews; Yan Li; Zhiyuan Hu; Whitney R Robinson; Katherine A Hoadley; Olufunmilayo I Olopade; Katherine E Reeder-Hayes; H Shelton Earp; Andrew F Olshan; Lisa A Carey; Charles M Perou Journal: J Natl Cancer Inst Date: 2018-02-01 Impact factor: 13.506
Authors: Rosemary D Cress; Yingjia S Chen; Cyllene R Morris; Helen Chew; Kenneth W Kizer Journal: Cancer Causes Control Date: 2016-04-20 Impact factor: 2.506
Authors: Andreana N Holowatyj; Michele L Cote; Julie J Ruterbusch; Kristina Ghanem; Ann G Schwartz; Fawn D Vigneau; David H Gorski; Kristen S Purrington Journal: J Clin Oncol Date: 2018-01-17 Impact factor: 44.544
Authors: Marc A Emerson; Katherine E Reeder-Hayes; Heather J Tipaldos; Mary E Bell; Marina R Sweeney; Lisa A Carey; H Shelton Earp; Andrew F Olshan; Melissa A Troester Journal: Curr Breast Cancer Rep Date: 2020-05-14
Authors: Steven J Katz; Timothy P Hofer; Yun Li; Allison W Kurian; Irina Bondarenko; Jeremy M G Taylor; Reshma Jagsi; Kevin C Ward; Ann S Hamilton Journal: Breast Cancer Res Treat Date: 2016-12-23 Impact factor: 4.624
Authors: Christopher R Friese; Yun Li; Irina Bondarenko; Timothy P Hofer; Kevin C Ward; Ann S Hamilton; Dennis Deapen; Allison W Kurian; Steven J Katz Journal: Cancer Date: 2016-10-24 Impact factor: 6.921
Authors: Nicholas Acuna; Jesse J Plascak; Jennifer Tsui; Antoinette M Stroup; Adana A M Llanos Journal: Int J Environ Res Public Health Date: 2021-05-12 Impact factor: 3.390